Aggressive iron dextran supplementation — Competitive Intelligence Brief

Aggressive iron dextran supplementation (Aggressive iron dextran supplementation) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Iron replacement agent. Area: Hematology.

marketed Iron replacement agent Iron (Fe3+) for hemoglobin and myoglobin synthesis Hematology Small molecule

Target snapshot

Aggressive iron dextran supplementation (Aggressive iron dextran supplementation) — Shanghai East Hospital. Iron dextran is a colloidal iron-carbohydrate complex that replenishes depleted iron stores by providing bioavailable iron for hemoglobin synthesis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Aggressive iron dextran supplementation TARGET	Aggressive iron dextran supplementation	Shanghai East Hospital	marketed	Iron replacement agent	Iron (Fe3+) for hemoglobin and myoglobin synthesis
Sodium ferric gluconate	Sodium ferric gluconate	University of North Carolina, Chapel Hill	marketed	Iron replacement agent	Iron (Fe3+) delivery system
Intravenous iron sucrose	Intravenous iron sucrose	Ain Shams University	marketed	Iron replacement agent
Iron Sucrose IV	Iron Sucrose IV	CN NGANOU-GNINDJIO, MD, MSc	marketed	Iron replacement agent	Transferrin receptor (indirect); iron supplementation
intravenous iron carboxymaltose	intravenous iron carboxymaltose	University of Zurich	marketed	Intravenous iron replacement agent	Iron (Fe³⁺) delivery system; transferrin receptor-mediated uptake
Generic sodium ferric gluconate	Generic sodium ferric gluconate	University of Maryland, Baltimore	marketed	Iron replacement agent	Iron (Fe3+) delivery; hemoglobin and myoglobin synthesis
Brand sodium ferric gluconate	Brand sodium ferric gluconate	University of Maryland, Baltimore	marketed	Iron replacement agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Iron replacement agent class)

1. University of Maryland, Baltimore · 2 drugs in this class
2. Ain Shams University · 1 drug in this class
3. American Regent, Inc. · 1 drug in this class
4. Azad Pharma AG · 1 drug in this class
5. CN NGANOU-GNINDJIO, MD, MSc · 1 drug in this class
6. China-Japan Friendship Hospital · 1 drug in this class
7. Hallym University Medical Center · 1 drug in this class
8. J. Uriach and Company · 1 drug in this class
9. JW Pharmaceutical · 1 drug in this class
10. Prince of Wales Hospital, Shatin, Hong Kong · 1 drug in this class